Site Operations
Keeping principal investigators engaged when enrollment stalls
Silence is the problem, not the pace
Every trial has slow stretches. Eligibility is narrow, a competing study opens, or the referral pattern simply takes time to build. A PI who understands that — because the site has shown the screening numbers, the referral sources, and the reasons candidates are failing — will usually stay patient.
What erodes engagement is silence. If the only time a PI hears about a study is when enrollment is behind, the study becomes associated with bad news. A short weekly update changes that, even when the update is that screening continues and no one enrolled this week. The trial stays visible, the PI stays connected to the work, and problems surface while they are still small enough to fix.
The update does not need to be long. Screening volume, referrals received, candidates in pre-screening, and one next step is enough. The discipline is regularity, not length.
Pay for defined activities, not only for enrollment
Compensation tied only to enrollment sends the wrong signal during a slow stretch: the PI and any partner practice do real work — chart review, pre-screening, referral conversations, study visits — and receive nothing because the enrolled count has not moved.
A better structure ties compensation to defined activities, each documented and priced at fair market value (FMV):
- Chart review and pre-screening, per completed review.
- Referral evaluation, where the practice assesses its own patients for eligibility.
- Study visits and procedures actually performed.
- Investigator oversight time the protocol requires, named as its own line.
This structure is fairer, and it is also easier to defend. Each payment corresponds to work that can be shown, at a rate that can be documented, rather than a single enrollment figure that rises and falls with factors the PI does not control. It also keeps partner practices willing to keep referring during a slow period, because the work of referring is itself recognized.
Ask what is actually slowing referrals
When referrals slow, sites often assume motivation and respond with encouragement or pressure. More often, the cause is workflow: eligibility criteria that are hard to check quickly, a referral step that adds work to a busy clinic, a coordinator who is hard to reach, or uncertainty about which patients to send.
The fastest way to find out is to ask the PI directly, in a short conversation with a specific question: what is making referrals harder than they should be? The answer is usually a fixable operational detail — a one-page eligibility summary, a simpler referral path, a faster pre-screening turnaround — not a motivation problem that needs a speech.
Fixing that detail does more for enrollment than any general push, and it tells the PI the site listens. That, in turn, is what keeps the next referral coming.
What engaged looks like
An engaged PI knows the current screening picture without having to ask, is paid promptly for defined work already done, and has a direct channel to raise a workflow problem and see it fixed. None of that requires a large program. It requires a regular update, an activity-based compensation structure documented at fair market value, and the habit of asking before assuming.
Slow enrollment tests that system. Sites that have it keep their investigators through the slow stretch and are ready when referrals pick up. Sites that do not often discover disengagement only when a referral that should have come goes somewhere else, or nowhere at all.
How this works in practice
At Amavita Research, our Miami cardiovascular trial site, we care for more than 18,000 active cardiology patients, and our record includes zero United States Food and Drug Administration (FDA) Form 483 findings. Our investigators and partner practices are part of how that record is built. Keeping them in the loop during slow enrollment, paying for defined activities rather than enrollment alone, and fixing workflow problems when they are raised is not extra work around the trial — it is part of running the trial well.
Julio G. Martinez-Clark is chief executive officer of Amavita Research Services, a Miami cardiovascular trial site, and chief executive officer of bioaccess, a first-in-human contract research organization.
Next step
Sponsors: see what Amavita Research can run
Amavita Research is a Miami cardiovascular trial site with 18,000+ active cardiology patients and zero United States Food and Drug Administration (FDA) Form 483 findings. See our site capabilities or talk with our sponsor team.